This decrease correlates with reduced levels of TGFβRI and TGFβRII receptors and alterations in SMAD3 and its phosphorylated variant, pSMAD3, further illustrating the contribution of EEF1A2 to increasing tumor aggressiveness [214]. The gene discussed is EEF1A2; the disease is neoplasm.